ABBISKO-B (02256) saw its shares climb nearly 8% during Tuesday's trading session, reflecting strong investor optimism following a positive clinical update. At the time of writing, the stock was up 7.05%, trading at HK$8.88, with a turnover of HK$10.43 million.

The rally comes after the company announced that its subsidiary, Abbisko Therapeutics, received encouraging preliminary efficacy results from a Phase II clinical study evaluating lavengratinib (ABSK061), a selective oral small-molecule FGFR2/3 inhibitor, in patients with achondroplasia, a common form of dwarfism. This development highlights the potential of the drug candidate in addressing an unmet medical need.

In a separate note, Zhongtai Securities recently revised its earnings forecast for ABBISKO-B, primarily to adjust the recognition timeline for milestone revenue related to the pimetinib licensing agreement, based on the company's revenue performance in the first half of 2026. The brokerage maintained a "Buy" rating, emphasizing that this adjustment does not alter the core pipeline value or the business development (BD) monetization logic. The newly announced multi-asset collaboration with Eli Lilly further underscores the advancement of the company's technology platform. As core assets continue to progress and subsequent milestones and partnership values gradually unlock, the company's medium-to-long-term growth narrative remains clear and compelling.